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Abstract: Seven new oxime-based acetylcholinesterase reactivators were compared with 
three currently available ones (obidoxime, trimedoxime, HI-6) for their ability to lessen 
cholinesterase inhibition in blood and brain of cyclosarin-treated rats. Oximes were given 
at doses of 5% their LD50 along with 21 mg/kg atropine five min before the LD50 of 
cyclosarin (120 ug/kg) was administered. Blood and brain samples were collected 30 
minutes later. The greatest difference between acetylcholinesterase inhibition in blood of 
cyclosarin-treated rats was found after administration of HI-6 (40%), compared to 22% for 
trimedoxime and 6% for obidoxime. Only two of the seven newly synthesized oximes had 
any effect (K203 at 7%, K156 at 5%). Effective oximes against cyclosarin-inhibited 
plasma butyrylcholinesterase were HI-6 (42%), trimedoxime (11%), and K156 (4%). The 
oximes were less effective in brain than in blood, with reactivation values for HI-6 30% 
against acetylcholinesterase and 10% against butyrylcholinesterase. Values for newly 
synthesized oximes were less than 10% for K206, K269 and K203. 
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1. Introduction  
 
Cholinesterase inhibitors based on phosphorus (OPI) are frequently used as insecticides in 
agriculture, industrial chemicals and some of these inhibitors with extremely high toxicity are called 
nerve agents. Nerve agents can be misused as chemical weapons or by terrorist groups. The 
mechanism of action of organophosphorus nerve agents (their toxicodynamics) is well known: 
irreversible inhibition of the enzyme acetylcholinesterase (AChE, EC 3.1.1.7) [1]. The inhibitory effect 
is based on phosphorylation or phosphonylation of serine hydroxyl group at the ester part of ChE 
active site of the enzyme [2]. 
The standard treatment of OPI intoxication usually consists of administration of anticholinergic 
drug (e.g. atropine) in combination with oximes. Anticholinergic drugs block effects of 
overstimulation caused by accumulated acetylcholine at peripheral muscarinic receptors while oximes, 
compounds with nucleophilic activity, repair the enzyme by dephosphorylation and restoring ChE’s 
activity [3]. However, the efficacy of commonly used oxime reactivators is still not sufficient [4]. 
Cyclosarin (GF agent; O-cyclohexyl-N,N-methyl phosphonofluoridate, Figure 1) belongs to a group 
of nerve agents or military importance that could be misused. The nerve agent cyclosarin has been 
examined to a minor extent compared to other nerve agents, e.g. sarin and soman. One reason is that 
this nerve agent was not regarded as a high priority chemical warfare agent until it was found to be 
stockpiled by Iraq in the early 1990s [5]. Commonly used bisquaternary reactivators (obidoxime, 
trimedoxime) of AChE are not able to counteract the toxic effect of cyclosarin because of their very 
low reactivating efficacy [6]. 
Figure 1. Chemical structure of cyclosarin. 
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There are many important structural factors which can influence the reactivation potency of oximes 
[7,8]. The developments of new and more effective AChE reactivator still continue. For these reasons, 
seven new reactivators of cyclosarin-inhibited ChE (K206, K269, K203, K075, K074, K027, K156) 
have been synthesized [9,10] to increase the reactivating efficacy of antidotal treatment of poisoning 
by this nerve agent. The aim of this study was to evaluate in vivo antidotal effects of currently 
available oximes (obidoxime, trimedoxime, HI-6) and the seven newly synthesized oximes in 
combination with atropine (commonly used anticholinergic drug) in cyclosarin-poisoned rats (Figure 
2). Syntheses as well as analyses of these reactivators were published formerly [9-14].
  
The other aim of this study was to compare antidotal effects of these compounds against cyclosarin-
inhibited butyrylcholinesterase (BChE; EC 3.1.1.8). BChE is in plasma and also in brain. These in vivo 
data could be useful for preparation of an effective pretreatment therapy including administration of 
pseudo-catalytic bioscavenger.  Int. J. Mol. Sci. 2009, 10                 
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Figure 2. Chemical structures of tested AChE reactivators: Commonly used oximes were 
HI-6, obidoxime and trimedoxime. Newly synthesized AChE reactivators were K206, 
K269, K203, K074, K075, K027 and K156. 
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2. Results and Discussion 
 
No symptoms of intoxication are manifest if AChE activity is decreased by about 20-30 % 
compared to normal AChE activity. The depression about 30-50 % is accompanied by muscarinic 
symptoms of intoxication. The subsequent depression about 50-70 % of original AChE activity is 
characterized by muscarinic, nicotinic and also central symptoms. Finally, inhibition under a 20 % 
limit leads to death of the intoxicated organism. If reactivation of inhibited AChE is considered, 
increase in reactivation to more than 10 % may save the life of intoxicated organism and can reduce 
toxic symptoms.  
The baseline AChE activity in blood was 13.15 ± 0.881 µcat/mL. Cyclosarin intoxication produced 
strong depression of AChE activity in blood. The activity decreased approximately to the one third of 
original activity (33%). Among the currently available oximes, HI-6 (40%) was found to be the best 
reactivator of the cyclosarin-inhibited AChE. If other commercial oximes are considered, the better 
one seems to be trimedoxime (22%) followed obidoxime (6%). From the group of the newly 
synthesized oximes, the best result was found after administration of K203 (7%). All other oximes, 
except oxime K156 (5%) were ineffective. Results are summarized in Figure 3. Int. J. Mol. Sci. 2009, 10                 
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Figure 3. Changes of AChE activities in whole blood after cyclosarin (GF) intoxication 
and administration of AChE reactivators.  
 
The absolute value of control, where only atropine (A) was applied (100%) was 13.15 ± 0.881 
µcat/ml. Values of results were expressed as mean ± SD, n = 6. AChE was inhibited on 35% of 
activity of control. The reactivation cyclosarin-inhibited AChE were found after administration of 
HI-6 (40%), obidoxime (6%), trimedoxime (22%), K203 (7%) and K156 (5%). The administration 
of other newly synthesized oximes was not effective. : K074 (-3%), K075 (-3%), K027 (-4%), 
K206 (-2%), K269 (-3%). The reactivation potency was compared to intoxicated group, treated 
only by atropine (A-GF). The significant changes in AChE activity were recorded between 
intoxicated group (A-GF) and groups treated by HI-6 and trimedoxime (p<0.001). 
 
The baseline BChE activity in plasma was 1.253 ± 0.252 µcat/mL. The BChE activity was also 
strongly decreased after cyclosarin intoxication. The residual activity of cyclosarin-inhibited BChE 
was 44 % in respect to original activity. From the currently available oximes, the oxime HI-6 (42%) 
achieved the best results again. Trimedoxime (11%) was also partially effective. All newly synthesized 
oximes were unable to reactivate cyclosarin-inhibited BChE and were as ineffective as the current 
commercially used obidoxime. Summarized results are shown in Figure 4. 
The baseline AChE activity in brain was 95.20 ± 4.357 and BChE activity was   
5.308 ± 0.474 µcat/ml. Strong inhibition of acetylcholinesterase (41%) was recorded in central nervous 
system (CNS). The results of all oximes are summarized in Figure 5 (AChE) and in Figure 6 (BChE). 
The inhibition of BChE (81%) was not so strong with respect to peripheral compartment (plasma). 
Only the oxime HI-6 (AChE 31%, BChE 10%) and trimedoxime (AChE 21%, BChE 11%) were able 
to partially protect cholinesterase in brain tissues. HI-6 seems to be the best reactivator again, because 
it was able to increase AChE activity for more than 30% in CNS. From the newly synthesized oximes 
only K206 and K269 were comparable with obidoxime (5%) reactivation potency.  
Generally, the efficacy of ChE reactivators depends on their reactivity and affinity towards 
organophosphate-inhibited enzyme. Their reactivity is derived from the nucleophilic activity of oxime 
anion that is bound on pyridinium ring [15]. They differ from each other by the position of the oxime 
group on the pyridinium ring and linker between pyridinium rings. The affinity of oximes for intact 
enzyme is determined by various physicochemical factors such as electrostatic attraction and Int. J. Mol. Sci. 2009, 10                 
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repulsion, hydrophobic interactions and by the shape and size of the whole molecule as well as the 
functional groups [21]. 
Figure 4. Changes of BChE activities in plasma after cyclosarin (GF) intoxication and 
administration of AChE reactivators.  
 
The absolute value of control, where only atropine (A) was applied (100%) was 1.253 ± 0.252 
µcat/ml. Values of results were expressed as mean ± SD, n = 6. AChE was inhibited on 44% of 
activity of control. The reactivation cyclosarin-inhibited AChE were found after administration of 
HI-6 (42%), trimedoxime (11%), K027 (1%) and K156 (4%). The administration of other oximes 
was not effective: obidoxime (-1%), K074 (-4%), K075 (-3%), K206 (-2%), K269 (0%) and K203 
(0%). The reactivation potency was compared to intoxicated group, treated only by atropine (A-
GF). The significant change in AChE activity was recorded between intoxicated group (A-GF) and 
group treated by HI-6 (p<0.001). 
 
Bisquaternary reactivators have higher affinity towards both intact and inhibited ChE and higher 
potency to reactivate nerve agent-inhibited ChE compared to monoquaternary ones [15]. All used 
reactivators are bisquaternary oximes and the two quaternary nitrogens in their structures increases 
affinity of the oxime reactivators to the inhibited cholinesterases. Quaternary nitrogen binds 
reactivator, as same as acetylcholine does, to the anionic site of the enzyme [7]. 
The number and position of the oxime group(s) on the pyridinium ring is other factor influencing 
the reactivation efficacy.  One oxime group in structure of AChE reactivator is necessary for the 
sufficient reactivation process [16].
 More important than the number is position of the oxime group on 
the rings. From the in vitro tests the reactivators with the oxime group in the position 2 are the best 
reactivators of cyclosarin-inhibited AChE [7] and best reactivation potency of tabun-inhibited AChE 
was observed for oximes with the oxime group in that position [17,18].
 Reactivators used in this 
comparative study, except HI-6, had oxime group in position 4. The results this in vivo study were 
compared with previously obtained in vitro results. None from the newly synthesized reactivators has 
better reactivation potency than the currently used HI-6 with its oxime group in position 2 on the 
pyridinium ring.  
 Int. J. Mol. Sci. 2009, 10                 
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Figure 5. Changes of AChE activities in brain after cyclosarin (GF) intoxication and 
administration of AChE reactivators.  
 
The absolute value of control where only atropine (A) was applied (100%) was 95.20 ± 4.357 
µcat/ml. Values of results were expressed as mean ± SD, n = 6. AChE was inhibited on 41% of 
activity of control. The reactivation cyclosarin-inhibited AChE were found after administration of 
HI-6 (31%), obidoxime (5%), trimedoxime (21%), K206 (4%) and K269 (5%). The administration 
of other newly synthesized oximes was not effective: K074 (-2%), K075 (-2%), K027 (-3%), K203 
(-2%), K156 (-4%). The reactivation potency was compared to intoxicated group, treated only by 
atropine (A-GF). The significant changes in AChE activity were recorded between intoxicated 
group (A-GF) and groups treated by HI-6 and trimedoxime (p<0.001). 
Figure 6. Changes of BChE activities in brain after cyclosarin (GF) intoxication and 
administration of AChE reactivators.  
 
The absolute value of control, where only atropine (A) was applied (100%) was 5.308 ± 0.474 
µcat/ml. Values of results were expressed as mean ± SD, n = 6. AChE was inhibited on 81% of 
activity of control. The reactivation cyclosarin-inhibited AChE were found after administration of 
HI-6 (10%), trimedoxime (11%), K075 (1%), K027 (3%) and K206 (4%), K203 (3%) and K156 
(2%). The administration of other oximes was not effective: obidoxime (-3%), K074 (-1%) and 
K269 (-1%). The reactivation potency was compared to intoxicated group, treated only by atropine 
(A-GF). The significant change in AChE activity was recorded between intoxicated group (A-GF) 
and group treated by trimedoxime (p<0.001). Int. J. Mol. Sci. 2009, 10                 
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The linking chain between two pyridinium rings is another important factor influencing oximes’ 
potency. Although this part of oxime reactivator molecule does not play any role in the 
dephosphorylation process, it is a major factor influencing reactivation rates [19,20]. There is also only 
one difference between the obidoxime and trimedoxime connection chains (linkers). Obidoxime has 
oxygen in the linking chain. Obidoxime reactivation potency in both the peripheral and also the central 
compartment was worse than the reactivation efficacy of trimedoxime. Similar molecular structures 
are the newly synthesized oximes K027 (one oxime group is replaced by an amidic group) and K156 
(there is only one oxime group in the molecule), but none of both oximes were able to reactivate 
cyclosarin-inhibited cholinesterases. It is clear, that presence of one oxime group is necessary for 
reactivation process. The presence of second one does not increase reactivation potency in the case of 
intoxication caused by tabun, but in cyclosarin-inhibited cholinesterases it can play positive role. 
The other change is a double bond in chain (oximes K206, K269, K203 and K075). Double bonds 
make the linker more rigid and change the reactivator´s conformation [21].
  This change in 
conformation can influence interaction between oxime and internal structure of enzyme. These oximes 
were ineffective in both compartments. The oxygen in the linker also can change oxime conformation. 
If we compare reactivation efficacy of obidoxime and trimedoxime, is clear that oxygen in the linker 
demonstrably decrease the reactivation potency [22].
  
The inhibitions of ChE in CNS after administration of cyclosarin were strong. The depression of 
AChE was stronger than inhibition of BChE. The reactivations of both ChE using newly synthesized 
oximes were not statistically significant. Only HI-6 and trimedoxime were able to partially protect the 
ChE in brain.  
 
3. Experimental Section 
 
3.1. Chemicals 
 
The nerve agent cyclosarin (GF agent; O-cyclohexyl-N,N-methyl phosphonofluoridate) of 97% 
purity was obtained from Military Technical Institute of Protection (Brno, Czech Republic) and stored 
in glass ampoules (0.3 mL). Its solution for experiments was prepared immediately before use due to 
the known spontaneous hydrolysis during long term storage. All other chemicals were obtained from 
Sigma-Aldrich (Prague, Czech Republic). Oximes were synthesized at the Department of Toxicology, 
Faculty of Military Health Sciences (Hradec Kralove, Czech Republic). The purity of prepared oximes 
was approximately 96-99% [9-14].
  
 
3.2. Animals 
 
Male Wistar rats, weighing from 180 to 200 g, were purchased from Anlab s.r.o. (Prague, Czech 
Republic). The animals were maintained in an air-conditioned room (the temperature were 22 ± 2 °C, 
the humidity was 50 ± 10%, with light from 7 a.m. to 7 p.m.), and were allowed free access to standard 
chow type SP 1, achieved from Velas s.r.o. (Prague, Czech Republic) and tap water. Housing of 
animals was realized in the Central Vivarium of Faculty of Military Health Sciences, Hradec Kralove. Int. J. Mol. Sci. 2009, 10                 
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The experiment was performed under permission and supervision of the Ethic Committee of the 
Faculty of Military Health Sciences, Hradec Kralove. 
 
3.3. Dosing and Sample Collection 
 
Although the main routes of administration of organophosphorus nerve agents are percutaneous or 
inhalation, we used intramuscular administration (i.m.) in our experiments, because there is better 
comparability with already available data [23]. A single dose of 1 × LD50 (120 µg/kg) of cyclosarin 
was injected i.m.. Before each experiment, actual cyclosarin toxicity determinations were done to 
prove that the dose to be administered really corresponds to the 1 × LD50 dose. Cyclosarin-induced 
toxicity was evaluated by the assessment of LD50  values and their confidence limits that were 
calculated by probit analysis by deaths occurring within 24 hours after administration of the nerve 
agent at five different doses, with six rats per dose [24,25]. 
Oximes in therapeutic dosages (5 % LD50) (Table 1) in combination with dose of atropine (21 
mg/kg) were administered i.m. 5 min before intoxication. First control group was treated only by dose 
of atropine and after 5 min was injected saline solution i.m. instead of nerve agent. The second control 
group of animals was also treated  with a dose of atropine and 5 min after cyclosarin was administered. 
Rats were anesthetized with CO2 and killed by decapitation 30 min after the nerve agent 
intoxication. The time interval, 30 min, of testing the reactivation potency of oximes was chosen based 
on our long-standing experiences. After decapitation, the trunk blood was collected in heparinized 
tubes and one part of this blood separated into plasma and erythrocytes by centrifugation (3000 × g for 
15 min, 15°C) with Universal 320R (Hettich, Germany). In the whole blood, the ratio between AChE 
and BChE is approximately 95:5. The brains were removed from the skulls and stored at -80°C until 
the assay [26]. 
Table 1. Oximes in therapeutic dosages corresponded to 5 % of LD50, these doses were 
administer to the animals. 
OXIME 
REACTIVATOR 
DOSE CORRESPONING TO 5 % OF 
LD50 
HI-6  39.0 mg/kg 
Obidoxime  10.5 mg/kg 
Trimedoxime  7.5 mg/kg 
K206  19.3 mg/kg 
K269  5.7 mg/kg 
K203  16.3 mg/kg 
K074  23.0 mg/kg 
K075  22.9 mg/kg 
K027  22.3 mg/kg 
K156  6.4 mg/kg 
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3.4. Biochemical Examinations 
 
The whole blood was measured the day when the samples were collected. The blood samples were 
hemolyzed by using 0.02M Tris buffer, pH 7.6 (ratio: 1:20) for 5 min. Plasma samples were stored as 
other tissues until the assay (-80°C). After thawing, brains were homogenized (weight of tissue: 
volume - 1: 10; 0.02M Tris buffer, pH 7.6). Each sample was mixed with Ultra–Turrax homogenizer 
(Janke & Kunkel, Germany) for 20 seconds. Homogenates were used for enzymatic analysis. The 
activities of AChE and BChE were assessed by standard spectrofotometric Ellman’s method with 
acetylthiocholine or butyrylthiocholine iodides as substrates and 5,5‘-dithiobis(2-nitrobenzoic) acid as 
a chromogen [27] modified in wavelength 436 nm (because of influence caused by hemoglobin). The 
spectrophotometer Helios Alpha (Electron Corporation, Great Britain) was used for determination of 
absorbancy. The results were calculated as µcat/ml of homogenate, hemolysate or plasma. 
 
3.5. Statistical Evaluation 
 
The percent of reactivation R was taken as an outputting parameter. The value of the R was 
calculated according following equation:  
(%) 100
0
×
Δ − Δ
Δ − Δ
=
Ai A
Ai A
R
r   (1) 
The symbol ∆A0 means absorbance provided by mixture with intact AChE (in this mixture was no 
inhibitor as well as no reactivator), ∆Ai is absorbance of mixture with inhibited AChE (no reactivator) 
and ∆Ar indicates AChE activity influenced by inhibitor and also reactivator [28]. The number of 
animals per group was six. Enzyme activities in tissue homogenates were expressed as the mean ± 
standard deviation (n=6). The ANOVA test was used for determination of statistical difference (Graph 
Pad Prism 4.0) (p<0.001). 
 
4. Conclusions 
 
In conclusion, the newly synthesized oximes were not able to surpass the efficacy of a currently 
used drug – HI-6.  Only trimedoxime in both compartments was partially effective.  Some newly 
synthesized oximes (K203; K156) were as effective as obidoxime in blood, which is not sufficient for 
treatment of cyclosarin-poisoning. No reactivation effect in central compartment was found after 
administration of all newly synthesized oximes. The partially protection of brain ChE was found only 
after administration of HI-6 and trimedoxime. 
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